Novartis Korea and Hanmi Pharmaceutical signed a strategic partnership for the sales of type 2 diabetes treatment 'Galvus' and 'Galvusmet’

Published: 2014-07-11 10:02:12

Updated: 2014-07-11 10:02:12

Novartis Korea and Hanmi Pharmaceutical signed a strategic partnership for the sales of type 2 diabetes treatment 'Galvus (vildagliptin)' and 'Galvusmet (vildagliptin / metformin)'.

Both companies' executive staffs attended the celebration for the strategic partnership and assured that they will take the first place in DPP-4 inhibitor family diabetes treatment market.

Galvus inhibits incretin...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.